Intelligence · Clinical Pipeline

MSD Merck Sharp Pipeline

All ClinicalTrials.gov programs at MSD Merck Sharp — phase, modality, and trial IDs.

Programs: 217

Quick answer

MSD Merck Sharp has 217 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

A clinical study of the V540A vaccine in healthy adults (V540A-001)

Merck Sharp and Dohme

Human Papilloma virus

phase 1 other active

1 trial
A clinical study of the V540C vaccine in healthy adults (V540C-003)

Merck Sharp and Dohme

Human Papilloma virus

phase 1 other active

1 trial
A clinical trial of MK-1824 in healthy participants (MK-1824-001)

Merck Sharp and Dohme

Heart failure with preserved ejection fraction

phase 1 other active

1 trial
A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)

Merck Sharp and Dohme

Hypercholesterolaemia

phase 1 other active

1 trial
A clinical trial of MK-4605 in healthy participants (MK-4605-001)

Merck Sharp and Dohme

Dementia

phase 1 other active

1 trial
A clinical trial of MK-6050 in healthy participants (MK-6050-002)

Merck Sharp and Dohme

Hidradenitis suppurativa

phase 1 other active

1 trial
A clinical trial of MK-6916 in healthy participants (MK-6916-010)

Merck Sharp and Dohme

Acute and Chronic pain

phase 1 other active

1 trial
A clinical trial of MK-7228 in adults (MK-7228-002)

Merck Sharp and Dohme

Atherosclerosis

phase 1 other active

1 trial
Anti-GD2 ADC M3554 in Advanced Solid Tumors

Merck Sharp and Dohme

Advanced Solid Tumors

phase 1 other active

1 trial
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Merck Sharp and Dohme

Advanced Solid Tumors

phase 1 other active

1 trial
Effect of Renal Impairment on Enpatoran Pharmacokinetics

Merck Sharp and Dohme

Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).

phase 1 other active

1 trial
LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, Bavencio 20 mg/mL concentrate for solution for infusion, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

Merck Sharp and Dohme

Central Nervous System Tumors

phase 1 small molecule active

1 trial
M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

Merck Sharp and Dohme

Advanced solid tumors

phase 1 other active

1 trial
M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Merck Sharp and Dohme

Advanced solid tumors and colorectal cancer

phase 1 other active

1 trial
MK-2420 SAD Study

Merck Sharp and Dohme

Rheumatoid arthritis

phase 1 other active

1 trial
MK-4318 CIDF Target Engagement Study

Merck Sharp and Dohme

Pain

phase 1 other active

1 trial
MK-4646 Single Ascending Dose Study and DDI in Healthy Participants

Merck Sharp and Dohme

HIV infection

phase 1 other active

1 trial
MK-7091 Formulations Study in Healthy Adult Participants

Merck Sharp and Dohme

Hypercholesterolemia

phase 1 other active

1 trial
MK-7480 Multiple Ascending Dose Study in Healthy Participants

Merck Sharp and Dohme

Non-alcoholic steatohepatitis

phase 1 other active

1 trial
Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

Merck Sharp and Dohme

Healthy

phase 1 other active

1 trial
Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

Merck Sharp and Dohme

Locally Advanced Squamous Cell Carcinoma of the Head and Neck

phase 1 other active

1 trial
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Merck Sharp and Dohme

Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

phase 1 other active

1 trial
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

Merck Sharp and Dohme

Advanced Solid Tumors

phase 1 other active

1 trial
Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Merck Sharp and Dohme

Metastatic or Locally Advanced Unresectable Solid Tumors

phase 1 other active

1 trial
CAPECITABINE, CALCIUM FOLINATE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, FLUOROURACIL, Lenvatinib, Lenvatinib, Calciumfolinat-GRY® 100 mg/10 ml Injektionslösung, OXALIPLATIN, Lenvatinib, CALCIUM LEVOFOLINATE , CAPECITABINE

Merck Sharp and Dohme

Advanced/Metastatic Gastroesophageal Adenocarcinoma

approved small molecule active

1 trial

Frequently asked questions

How many pipeline programs does MSD Merck Sharp have?

217 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Quick answer

A clinical study of the V540A vaccine in healthy adults (V540A-001)

A clinical study of the V540C vaccine in healthy adults (V540C-003)

A clinical trial of MK-1824 in healthy participants (MK-1824-001)

A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)

A clinical trial of MK-4605 in healthy participants (MK-4605-001)

A clinical trial of MK-6050 in healthy participants (MK-6050-002)

A clinical trial of MK-6916 in healthy participants (MK-6916-010)

A clinical trial of MK-7228 in adults (MK-7228-002)

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Effect of Renal Impairment on Enpatoran Pharmacokinetics

LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, Bavencio 20 mg/mL concentrate for solution for infusion, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

MK-2420 SAD Study

MK-4318 CIDF Target Engagement Study

MK-4646 Single Ascending Dose Study and DDI in Healthy Participants

MK-7091 Formulations Study in Healthy Adult Participants

MK-7480 Multiple Ascending Dose Study in Healthy Participants

Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

CAPECITABINE, CALCIUM FOLINATE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, FLUOROURACIL, Lenvatinib, Lenvatinib, Calciumfolinat-GRY® 100 mg/10 ml Injektionslösung, OXALIPLATIN, Lenvatinib, CALCIUM LEVOFOLINATE , CAPECITABINE

Frequently asked questions

Stay Ahead in Pharma